AZD4635 Plus Durvalumab and Cabazitaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer
ESMO Open 2024 Jun 04;9(6)103446, T Alonso-Gordoa, M Goodman, C Vulsteke, G Roubaud, J Zhang, M Parikh, JM Piulats, A Azaro, GD James, R Cavazzina, ET Gangl, J Thompson, G Pouliot, R Kumar, C SweeneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.